https://doi.org/10.1136/bmj.n597
BMJ (Clinical Research Ed.); Mahase E
Mar 4th, 2021 - Covid-19: Where are we on vaccines and variants?|2021|Mahase E,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314739
The New England Journal of Medicine; Lopez Bernal J, Andrews N et. al.
Jul 22nd, 2021 - The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vacc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934118
Nature Reviews. Immunology; Teijaro JR, Farber DL
Mar 7th, 2021 - COVID-19 vaccines: modes of immune activation and future challenges.|2021|Teijaro JR,Farber DL,|immunology,immunology,immunology,prevention & control,immunology,therapeutic use,immunology,immunology,immunology,immunology,immunology,immunology,immunology,
https://www.nejm.org/doi/10.1056/NEJMoa2108891
The New England Journal of Medicine;
Aug 12th, 2021 - The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vacc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454645
The New England Journal of Medicine; Barouch DH
Sep 1st, 2022 - Covid-19 Vaccines - Immunity, Variants, Boosters.|2022|Barouch DH,|immunology,prevention & control,virology,immunology,therapeutic use,
https://doi.org/10.1097/MCP.0000000000000868
Current Opinion in Pulmonary Medicine; Rudan I, Adeloye D et. al.
Feb 25th, 2022 - We reviewed three leading strategies of vaccine development against coronavirus disease 2019 (COVID- 19): mRNA vaccines, adenoviral vector vaccines and recombinant nanoparticles. We also considered the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and their impact on the effectiveness of the most widely implemented ...
https://www.medscape.com/viewarticle/964707
Dec 15th, 2021 - The COVID-19 pandemic has entered a new phase, which for many is particularly confusing. After the improvements seen at the end of summer, a new wave is surfing the planet and a potentially dangerous variant has emerged in South Africa, which has the experts worried. Weren't vaccines supposed to solve everything? Why are we still feeling like we keep going back to square on...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646685
Reviews in Medical Virology; Hadj Hassine I
Nov 11th, 2021 - Since the outbreak of coronavirus disease 2019 (Covid-19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid-19 vaccine candidates based on the original Wuhan-Hu-1 strain are at t...
https://doi.org/10.1056/NEJMe2300211
The New England Journal of Medicine; Rubin EJ, Baden LR et. al.
Jan 12th, 2023 - Audio Interview: Covid-19 Vaccines and New Viral Variants.|2023|Rubin EJ,Baden LR,Morrissey S,|genetics,prevention & control,virology,therapeutic use,genetics,
https://directorsblog.nih.gov/2021/05/04/a-real-world-look-at-covid-19-vaccines-versus-new-variants/
NIH Director's Blog;
May 4th, 2021 - Clinical trials have shown the COVID-19 vaccines now being administered around the country are highly effective in protecting fully vaccinated individuals from the coronavirus SARS-CoV-2. But will they continue to offer sufficient protection as the frequency of more transmissible and, in some cases, deadly emerging variants rise? More study and time is needed to full...
https://doi.org/10.1001/jama.2021.3370
JAMA Rubin R
Mar 18th, 2021 - COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough.|2021|Rubin R,|immunology,prevention & control,transmission,immunology,prevention & control,genetics,immunology,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877693
Journal of Paediatrics and Child Health; Isaacs D, Britton PN
Dec 6th, 2022 - Perceptions of risk around COVID-19 and COVID-19 vaccines.|2022|Isaacs D,Britton PN,|prevention & control,
https://doi.org/10.1055/s-0042-1759779
Seminars in Respiratory and Critical Care Medicine; Shishido AA, Barnes AH et. al.
Jan 17th, 2023 - The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic has led to an unprecedented public health crisis. The collective global response has led to production of multiple safe and effective vaccines utilizing novel platforms to combat the virus that have propelled the field of vaccinology forward. Significant challenges to universal vaccine effectiveness remain, includi...
https://emedicine.medscape.com/article/2500139-overview
Jan 13th, 2023 - Overview After publication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic sequence on January 11, 2020, research and collaboration among scientists and biopharmaceutical manufacturers quickly followed. Various methods are used for vaccine discovery and manufacturing. [1] Two mRNA vaccines (Comirnaty by Pfizer and Spikevax by Moderna) that have gained full app...
http://emedicine.medscape.com/article/2500139-overview
Jan 13th, 2023 - Overview After publication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic sequence on January 11, 2020, research and collaboration among scientists and biopharmaceutical manufacturers quickly followed. Various methods are used for vaccine discovery and manufacturing. [1] Two mRNA vaccines (Comirnaty by Pfizer and Spikevax by Moderna) that have gained full app...
https://emedicine.medscape.com/article/2500139-print
Jan 13th, 2023 - After publication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic sequence on January 11, 2020, research and collaboration among scientists and biopharmaceutical manufacturers quickly followed. Various methods are used for vaccine discovery and manufacturing.[1] Two mRNA vaccines (Comirnaty by Pfizer and Spikevax by Moderna) that have gained full approval by t...
https://doi.org/10.1136/bmj.o2422
BMJ (Clinical Research Ed.); Looi MK, Mahase E
Oct 21st, 2022 - What next for covid-19 vaccines?|2022|Looi MK,Mahase E,|prevention & control,
https://emedicine.medscape.com/article/2500142-print
Dec 28th, 2022 - Coronavirus 2019 (COVID-19) disease is the clinical illness caused by the novel coronavirus that was initially called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; SARS-2).[1, 2] SARS-CoV-1 (SARS-1), a different strain of coronavirus, caused illness during 2002-2004. It also caused severe respiratory disease, then essentially eradicated.[3] COVID-19...
http://emedicine.medscape.com/article/2500142-overview
Dec 28th, 2022 - Coronavirus-2019 (COVID-19) Coronavirus 2019 (COVID-19) disease is the clinical illness caused by the novel coronavirus that was initially called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; SARS-2). [1, 2] SARS-CoV-1 (SARS-1), a different strain of coronavirus, caused illness during 2002-2004. It also caused severe respiratory disease, ...
https://emedicine.medscape.com/article/2500142-overview
Dec 28th, 2022 - Coronavirus-2019 (COVID-19) Coronavirus 2019 (COVID-19) disease is the clinical illness caused by the novel coronavirus that was initially called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; SARS-2). [1, 2] SARS-CoV-1 (SARS-1), a different strain of coronavirus, caused illness during 2002-2004. It also caused severe respiratory disease, ...
